Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Clinical trial NCT01401166 · COMPLETED

Trial details

NCT number: NCT01401166
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Neoplasms

Start date: 2011-10-01
Primary completion: 2013-05-01
Enrollment: 488

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.